Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Brenu, Ekua W ^a   van Driel, Mieke L ^a   Staines, Don R ^a,b   Ashton, Kevin J ^a   Ramos, Sandra B ^a   Keane, James ^a   Klimas, Nancy G ^c   Marshall Gradisnik, Sonya M ^a  

^a BOND UNIVERSITY   (Australia)

^b QUEENSLAND HEALTH   (Australia)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANZYME; GRANZYME A; GRANZYME K; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; NEUROPEPTIDE; PERFORIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; MITOGENIC AGENT;

ADULT; AGED; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CHRONIC FATIGUE SYNDROME; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE MARKER; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FATIGUE SYNDROME, CHRONIC; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MITOGENS; PHENOTYPE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RNA, MESSENGER;

EID: 79957440333     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-81     Document Type: Article

References (52)

1. Grinde B. Is chronic fatigue syndrome caused by a rare brain infection of a common, normally benign virus?. Med Hypotheses 2008, 71(2):270-274. 10.1016/j.mehy.2008.03.014, 18440157.
2. Devanur LD, Kerr JR. Chronic fatigue syndrome. J Clin Virol 2006, 37(3):139-150. 10.1016/j.jcv.2006.08.013, 16978917.
3. Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S. The Economic impact of ME/CFS: Individual and societal costs. Dyn Med 2008, 7:6. 10.1186/1476-5918-7-6, 2324078, 18397528.
4. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994, 121(12):953-959.
5. Arnett SV, Alleva LM, Korossy-Horwood R, Clark IA. Chronic fatigue syndrome - A neuroimmunological model. Med Hypotheses 2011,
6. Biswal B, Kunwar P, Natelson BH. Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. J Neurol Sci 2011, 301(1-2):9-11. 10.1016/j.jns.2010.11.018, 21167506.
7. Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab (Lond) 2010, 7:79.
8. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8(4):287-291. 10.1016/j.autrev.2008.08.003, 18801465.
9. Natelson BH, Weaver SA, Tseng CL, Ottenweller JE. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin Diagn Lab Immunol 2005, 12(1):52-55. 540195, 15642984.
10. Schutzer SE, Angel TE, Liu T, Schepmoes AA, Clauss TR, Adkins JN, Camp DG, Holland BK, Bergquist J, Coyle PK, Smith RD, Fallon BA, Natelson BH. Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome. PLoS One 2011, 6(2):e17287. 10.1371/journal.pone.0017287, 3044169, 21383843.
11. Sorensen B, Jones JF, Vernon SD, Rajeevan MS. Transcriptional control of complement activation in an exercise model of chronic fatigue syndrome. Mol Med 2009, 15(1-2):34-42. 2583111, 19015737.
12. Nijs J, van Eupen I, Vandecauter J, Augustinus E, Bleyen G, Moorkens G, Meeus M. Can pacing self-management alter physical behavior and symptom severity in chronic fatigue syndrome? A case series. J Rehabil Res Dev 2009, 46(7):985-996. 10.1682/JRRD.2009.01.0007, 20104421.
13. Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, Christy RM, Marshall-Gradisnik SM. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med 2010, 8:1. 10.1186/1479-5876-8-1, 2829521, 20064266.
14. Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, Broderick G, Klimas NG. Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One 2010, 5(5):e10817. 10.1371/journal.pone.0010817, 2876037, 20520837.
15. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990, 28(6):1403-1410. 267940, 2166084.
16. Maher KJ, Klimas NG, Fletcher MA. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol 2005, 142(3):505-511. 1440524, 16297163.
17. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in Chronic Fatigue Syndrome. Brain Behav Immun 2010,
18. Kuratsune H. Overview of chronic fatigue syndrome focusing on prevalence and diagnostic criteria. Nippon Rinsho 2007, 65(6):983-990.
19. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann N Y Acad Sci 2006, 1070:51-74. 10.1196/annals.1317.031, 16888149.
20. Staines DR. Is chronic fatigue syndrome an autoimmune disorder of endogenous neuropeptides, exogenous infection and molecular mimicry?. Med Hypotheses 2004, 62(5):646-652. 10.1016/j.mehy.2004.01.012, 15082083.
21. Aubry JP, Blaecke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G, Moine V, Bonnefoy JY. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 1999, 37(3):197-204. 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L, 10520200.
22. White L, Krishnan S, Strbo N, Liu H, Kolber MA, Lichtenheld MG, Pahwa RN, Pahwa S. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood 2007, 109(9):3873-3880. 10.1182/blood-2006-09-045278, 1874576, 17192392.
23. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97(10):3146-3151. 10.1182/blood.V97.10.3146, 11342442.
24. Sun W, Hong J, Zang YC, Liu X, Zhang JZ. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 2006, 18(12):1691-1700. 10.1093/intimm/dxl103, 17077178.
25. Collins DP, Luebering BJ, Shaut DM. T-lymphocyte functionality assessed by analysis of cytokine receptor expression, intracellular cytokine expression, and femtomolar detection of cytokine secretion by quantitative flow cytometry. Cytometry 1998, 33(2):249-255. 10.1002/(SICI)1097-0320(19981001)33:2<249::AID-CYTO21>3.0.CO;2-T, 9773887.
26. Okwor I, Muleme H, Jia P, Uzonna JE. Altered proinflammatory cytokine production and enhanced resistance to Trypanosoma congolense infection in lymphotoxin beta-deficient mice. J Infect Dis 2009, 200(3):361-369. 10.1086/599792, 19563258.
27. Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol 2004, 135(2):294-302. 10.1111/j.1365-2249.2004.02354.x, 1808936, 14738459.
28. Swanink CM, Vercoulen JH, Galama JM, Roos MT, Meyaard L, van der Ven-Jongekrijg J, de Nijs R, Bleijenberg G, Fennis JF, Miedema F, van der Meer JW. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis 1996, 173(2):460-463. 10.1093/infdis/173.2.460, 8568312.
29. Nakamura T, Schwander SK, Donnelly R, Ortega F, Togo F, Broderick G, Yamamoto Y, Cherniack NS, Rapoport D, Natelson BH. Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia. Clin Vaccine Immunol 17(4):582-587.
30. Drulovic J, Savic E, Pekmezovic T, Mesaros S, Stojsavljevic N, Dujmovic-Basuroski I, Kostic J, Vasic V, Stojkovic MM, Popadic D. Expression of T(H)1 and T(H)17 cytokines and transcription factors in multiple sclerosis patients: Does baseline T-Bet mRNA predict the response to interferon-beta treatment?. J Neuroimmunol 2009, 215(1-2):90-95. 10.1016/j.jneuroim.2009.07.010, 19695714.
31. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res 2009, 15(6):1931-1939. 10.1158/1078-0432.CCR-08-1980, 2757059, 19240164.
32. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008, 112(5):1557-1569. 10.1182/blood-2008-05-078154, 2518872, 18725574.
33. Paust HJ, Turner JE, Steinmetz OM, Peters A, Heymann F, Holscher C, Wolf G, Kurts C, Mittrucker HW, Stahl RA, Kurts C, Panzer U. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol 2009, 20(5):969-979. 10.1681/ASN.2008050556, 2678032, 19339380.
34. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, Moles JP, Danger Y, Ravon E, Lesaux S, Yssel H, Gascan H. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008, 180(11):7423-7430.
35. Kaushik N, Fear D, Richards SC, McDermott CR, Nuwaysir EF, Kellam P, Harrison TJ, Wilkinson RJ, Tyrrell DA, Holgate ST, Kerr JR. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol 2005, 58(8):826-832. 10.1136/jcp.2005.025718, 1770875, 16049284.
36. Kerr JR. Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis. Curr Rheumatol Rep 2008, 10(6):482-491. 10.1007/s11926-008-0079-5, 19007540.
37. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol 2008, 180(9):5771-5777.
38. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006, 22(8):757-762. 10.1089/aid.2006.22.757, 2431151, 16910831.
39. den Haan JM, Kraal G, Bevan MJ. Cutting edge: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. J Immunol 2007, 178(9):5429-5433. 2776046, 17442923.
40. Szkaradkiewicz A, Karpinski TM, Drews M, Borejsza-Wysocki M, Majewski P, Andrzejewska E. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J Biomed Biotechnol 2010, 901564.
41. Scully P, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG, Quigley EM. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 105(10):2235-2243.
42. Goehler LE, Lyte M, Gaykema RP. Infection-induced viscerosensory signals from the gut enhance anxiety: implications for psychoneuroimmunology. Brain Behav Immun 2007, 21(6):721-726. 10.1016/j.bbi.2007.02.005, 1986672, 17428636.
43. Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab (Lond) 7:79.
44. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 1999, 162(3):1707-1716.
45. Pozo D, Delgado M, Martinez M, Guerrero JM, Leceta J, Gomariz RP, Calvo JR. Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today 2000, 21(1):7-11. 10.1016/S0167-5699(99)01525-X, 10637552.
46. Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. FASEB J 2004, 18(12):1325-1334. 10.1096/fj.03-1440hyp, 15333575.
47. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007, 13(6):241-251. 10.1016/j.molmed.2007.04.003, 17467339.
48. Nancy AL, Shoenfeld Y. Chronic fatigue syndrome with autoantibodies--the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 2008, 8(1):52-55. 10.1016/j.autrev.2008.07.026, 18725327.
49. Buskila D, Atzeni F, Sarzi-Puttini P. Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun Rev 2008, 8(1):41-43. 10.1016/j.autrev.2008.07.023, 18706528.
50. Scott GB, Meade JL, Cook GP. Profiling killers; unravelling the pathways of human natural killer cell function. Brief Funct Genomic Proteomic 2008, 7(1):8-16. 10.1093/bfgp/elm037, 18208863.
51. Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 2008, 26:389-420. 10.1146/annurev.immunol.26.021607.090404, 2790083, 18304003.
52. Saiki T, Kawai T, Morita K, Ohta M, Saito T, Rokutan K, Ban N. Identification of marker genes for differential diagnosis of chronic fatigue syndrome. Mol Med 2008, 14(9-10):599-607. 2442021, 18596870.